Abstract Activation of tumor-reactive T lymphocytes is a promising approach for the prevention and treatment of patients with metastatic cancers. 
+ tumor cells that are transduced with costimulatory molecules and MHC II alleles syngeneic to the prospective recipient. Because the vaccine cells do not express the MHC II-associated invariant chain (Ii), we hypothesized that they will present endogenously synthesized tumor peptides that are not presented by professional Ii + antigen presenting cells (APC) and will therefore overcome tolerance to activate CD4 + T cells. We now report that MHC II vaccines prepared from human MCF10 mammary carcinoma cells are more eYcient than Ii + APC for priming and boosting Type 1 CD4 + T cells. MHC II vaccines consistently induce greater expansion of CD4 + T cells which secrete more IFN and they activate an overlapping, but distinct repertoire of CD4 + T cells as measured by T cell receptor V usage, compared to Ii
Introduction
Successful cancer vaccines must induce potent tumor-speciWc immunity and long term immunological memory to protect against recurrent tumors and metastatic disease. Many vaccines are aimed at boosting cell-mediated immunity, which is considered particularly promising due to its ability to destroy tumor cells. Type 1 CD4 + T cells, which secrete IFN , have long been recognized as critical components for the activation of CD8 + T cells, either through their classical role as "helper" T cells that provide cytokine support for CD8 + T cells [6, 22] , or by their induction of CD40 expression on dendritic cells (DC) ("licensing"), which in turn activate CD8 + T cells [5, 36, 40] . CD4 + T cells are also essential for generating CD8 + T memory cells, for preventing CD8 + T cells from being tolerized [3, 19-21, 41, 44, 45] , and for recruiting cells of the innate immune system, such as macrophages. IFN production at the tumor site also up-regulates tumor-expressed MHC molecules to improve CTL recognition, and blocks neo-vascularization to prevent tumor proliferation [18, 34, 35] . Because of the central role of CD4 + T cells in facilitating anti-tumor immunity, we are developing vaccine strategies that speciWcally activate CD4 + T cells. Activation of CD4 + T cells requires two signals: an antigen-speciWc signal delivered by a major histocompatibility complex class II (MHC II) molecule presenting a speciWc peptide, and a costimulatory signal. Expression of MHC II and costimulatory molecules is usually limited to professional antigen presenting cells (APC), such as DC. Therefore, activation of tumor-reactive CD4 + T cells requires that tumor antigens are endocytosed by DC and processed and presented to the appropriate CD4 + T cells [37] . Presentation of exogenously acquired antigen by DC is facilitated by the expression of the MHC II accessory molecule invariant chain (Ii). As newly synthesized MHC II molecules enter the endoplasmic reticulum (ER), their peptide-binding groove is occupied by Ii. From the ER, MHC II/Ii complexes traYc to endosomal compartments where Ii is degraded, and peptides derived from endocytosed, exogenously synthesized molecules are loaded with the help of HLA-DM [10] . As a result, CD4 + T cells that are activated by professional APC react with antigens obtained from third party (e.g. tumor) cells, but the actual peptides for which the CD4 + T cells are speciWc, are generated by DC. Tumors synthesize antigens that are immunogenic and under some circumstances can activate an immune response that mediates tumor rejection [16, 38] . However, many tumor-bearing individuals are tolerized to the tumorderived peptides presented by their DC, and do not produce tumor-reactive CD4 + T cells [42, 43] . We are developing cell-based "MHC II vaccines" that are designed to overcome an individual's tolerance to their tumor peptides. The MHC II vaccines are tumor cells that are genetically modiWed to express MHC II and costimulatory molecules. In professional APC which are Ii + , peptides derived from exogenously synthesized molecules are processed in endosomes where they bind to MHC II molecules. Because the vaccine cells do not express Ii, we have hypothesized that MHC II molecules bind peptides in the ER that are derived from endogenously synthesized proteins [1, 32, 33] . Since ER-resident peptides are likely to diVer from endosomally generated peptides [9] , the vaccines may present novel peptides that are not presented by professional Ii positive APC. Therefore, the vaccine cells should activate a diVerent population of CD4 + T cells than that activated by Ii positive APC, thereby overcoming tolerance and stimulating tumor-speciWc immunity.
In previous reports MHC II vaccines were shown to have signiWcant therapeutic eYcacy in mouse models against large, established primary [2] and spontaneously metastatic [30, 31] tumors. We have recently adapted the MHC II vaccine approach for human tumors and have developed several vaccines for human mammary carcinoma and ocular melanoma [13] . Similar to the mouse vaccines, the human MHC II vaccines eYciently present endogenously synthesized tumor peptides, and activate tumor-reactive CD4 + T cells from healthy donors [47] and from patients with primary or metastatic cancer [8] . In this report we demonstrate that human Ii negative MHC II vaccine cells are signiWcantly better activators of tumor-reactive Type 1 CD4 + T cells than are Ii positive APC, and that the Ii negative vaccine cells activate an overlapping, but distinct, repertoire of CD4 + T cells than is activated by Ii positive APC. These Wndings support our hypothesis that Ii negative MHC II vaccine cells present some tumor peptides that are not presented by professional Ii positive APC and therefore may be eVective therapeutic and/or prophylactic agents for cancer patients.
Materials and methods

Cells
The human tumor cell lines Sweig and Jurkat, peripheral blood mononuclear cells (PBMC) from healthy human donors [13] , MCF10CA1 human mammary carcinoma (hereafter called MCF10), and MCF10 transductants [47] were handled as described. MCF10/CIITA/CD80/Ii siRNA cells are MCF10/CIITA/CD80 cells that were rendered Ii negative by transduction with Ii siRNA 32. MHC II and Ii siRNA transductants were previously shown to express stable MHC II heterodimers and not express Ii as assayed by western blotting and Xow cytometry [47] . PBMC were obtained by venipuncture from healthy human donors and buVy coats were stored in liquid nitrogen until used. Thawed PBMC were >90% viable. All cell lines and procedures were approved by the institutional review boards of the participating institutions.
Retroviral constructs, transductions and drug selection
The human major histocompatibility complex class II associated invariant chain (Ii) cDNA (Genbank accession no. NID X00497), containing both start codons for p33 and p35 isoforms of Ii, was cloned from sp64/p33 (kindly provided by Eric Long, NIH) [23] , into the pLPCX vector (Clontech) containing a puromycin resistance gene. To construct the pLPCX/ Ii vector containing the Ii gene, Ii was excised from sp64/p33 with SalI and EcoRI (New England Biolabs; Beverly, MA, USA) and inserted into the pLPCX vector digested with XhoI (New England Biolabs) and EcoRI (XhoI having compatible cohesive ends with SalI). Proper insertion of the Ii gene was conWrmed by sequence analysis. Sequencing reactions were carried out using the "ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit V3.1" (Perkin Elmer Applied Biosystems Division, Foster City, CA, USA) according to the manufacturer's protocol using a PTC-200 Thermal Cycler (MJ Research, BioRad, Hercules, CA, USA) and an ABI PRISM 3700 DNA Analyzer (Applied Biosystem). Retroviruses were prepared, and tumor cells were transduced with the retroviruses as described [13] . Transduced cells were selected in 0.3 g/ml puromycin for 2-3 weeks after transduction, and thereafter maintained in MCF10 medium without puromycin. Transduced cells were periodically monitored by Xow cytometry for expression of the transduced genes, which were stably expressed for >12 months.
Antibodies, immunoXuorescence, western blots HLA-DR-FITC, CD80-PE, FITC-isotype and PE-isotype controls were from BD Biosciences. CD4-FITC and CD8-FITC were from Miltenyi Biotec Inc. (Auburn, CA, USA); HLA-DM-PE was from BDBiosciences (San Diego, CA, USA). Culture supernatants of hybridomas W6/32 (pan HLA-A, B, C), L243 (pan anti-HLA-DR), and PIN1.1 (anti-Ii) were prepared, and tumor cells and PBMC were stained for cell surface markers, or Wxed and stained for Ii as described [13] . T cell receptor (TCR) V repertoire of CD4 + T cells was determined by three color Xow cytometry analysis using the IO Test Beta Mark TCR V Repertoire kit (Beckman Coulter, San Diego, CA, USA), which consists of monoclonal antibodies (mAbs) to 24 distinct TCR V families (about 70% coverage of normal human TCR V repertoire). Each test includes three directly coupled TCR V mAbs, conjugated to PE, FITC or both PE and FITC. PBMC were stained and analyzed for TCR V usage according to the manufacturer's instructions, with the following modiWcation: prior to staining with V mAbs, 1 £ 10 5 PBMC were stained with 1 g of biotin conjugated anti-human CD4 (eBiosciense, SanDiego, CA, USA), then washed and stained with streptavidin-PerCP (BD). Viable CD4 + T cells were gated according to CD4 staining and side scatter, and this population was analyzed for V TCR usage. Western blots were done as described [47] .
T cell priming and T cell depletions
Transduced MCF10, (MCF10/DR7/CD80, MCF10/DR7/ CD80/Ii, MCF10/CIITA/CD80, and MCF10/CIITA/CD80/ Ii siRNA) cells were plated on day 0 in MCF10 medium at 2-4 £ 10 5 cells/4 ml in 6 cm dishes and the cells allowed to attach before irradiating with 25 Gy. The next morning MCF10 medium was removed and 1-2 £ 10 7 PBMC in 4 ml of T cell medium (Isocoves ModiWed Dulbeccos Medium, 1% gentamicin, 1% penicillin, 2 mM Glutamax, 0.01 M HEPES, 1 mM sodium pyruvate (Invitrogen, Carlsbad, CA, USA), 0.05 mM mercaptoethanol (VWR West Chester, PA, USA), 5% human AB serum (Genini BioProducts Woodland, CA, USA) were added to each 6 cm dish, and the cells were incubated at 37°C for 3-5 days. At the end of this incubation period, non-adherent cells (PBMC) were harvested, washed twice, and resuspended at 1 £ 10 6 PBMC/2 ml T cell medium supplemented with human recombinant IL-15 (40 ng/2 ml) (Peprotech, Rocky Hill, NJ, USA). PBMC were then plated in 24 well plates at 1 £ 10 6 cells/2 ml/well. After a 7 day culture period, the non-adherent cells ("primed PBMC") were removed, washed twice, and then rested in T cell medium for 1-3 days before being used in antigen presentation assays. In some experiments, PBMC were depleted for CD4 + or CD8 + T cells before priming, using LD columns and CD4 or CD8 microbeads according to the manufacturers' directions (Miltenyi, Auburn, CA, USA).
Antigen presentation assays MHC II vaccine cells were plated at 2.5 £ 10 4 cells/200 MCF10 medium/well in 96 well plates and allowed to adhere for 2-4 h. MCF10 medium was then removed and primed PBMC in T cell medium were added at 5 £ 10 4 PBMC/200 l/well. After 48 h of incubation, the supernatants were analyzed for IFN by ELISA [13] , and the non-adherent cells were analyzed for TcR V repertoire by Xow cytometry. Multiplex cytokine analyses were done in the Cytokine Core Facility at the University of Maryland, Baltimore using the Luminex 100 System (Luminex, Austin, TX, USA) according to the manufacturer's directions.
HLA haplotyping PBMC from healthy donors and MCF10 cell lines were HLA typed using SSP-ABDR DNA typing trays (OneLambda, Canoga Park, CA, USA) according to the manufacturer's recommendations. MCF10 are A33, B55, DR7. PBMC 100704 are A11, A29; B44, B51; DR4, DR7, DR53. PBMC 111504 are A1, A68; B35, B57; DR1, DR7, DR53; PBMC 123104 are A33, A36; B-, B44; DR1, DR7, DR53.
Statistical analysis and TCR V usage calculations
Mean, SD, and statistical signiWcance as measured by Student's t test were calculated using Excel v2002. Percent increase in TCR V usage = 100% £ [(% cells with speciWc TCR V after activation with Ii ¡ or Ii + APC)/(% cells with speciWc TCR V before activation)].
Results
MCF10 human mammary carcinoma cells transduced with an Ii (p33) expression vector express Ii
To study the eVects of Ii on the repertoire of peptides presented by MHC II-transduced human breast cancer cells, we have constructed an expression vector that contains p33, which is the dominant isoform of Ii [23] (Fig. 1a) . MCF10 cells previously transduced with retroviruses encoding MHC II and CD80 molecules (MCF10/DR7/CD80) were further transduced with Ii retroviruses. The resulting cells (MCF10/DR7/CD80/Ii) were stained with mAbs for cell surface expression of HLA-DR, HLA-DM, and CD80 (live cells), or for internal Ii expression (Wxed cells), and analyzed by Xow cytometry (Fig. 1b) . MCF10/DR7/CD80/Ii cells express Ii protein, and their levels of HLA-DR and CD80 are similar to the levels expressed by Ii ¡ MCF10/ DR7/CD80 cells. Neither population expresses HLA-DM. Expression of the Ii p33 isoform by MCF10/DR7/CD80/Ii cells was further conWrmed by western blotting using the human B cell lymphoma cell line Sweig as a positive control for p33 (Fig. 1c) In professional APC such as DC, HLA-DM facilitates the binding of peptides derived from exogenously synthesized molecules by displacing the class II-associated Ii peptide (CLIP) from the peptide binding groove of MHC II molecules [10] . Since MCF10/DR7/CD80/Ii vaccine cells contain Ii, but do not contain DM (Fig. 1b) , their reduced antigen presentation activity may be due to an inability to replace CLIP with other peptides. If MCF10/DR7/CD80/Ii cells have this defect and are unable to replace CLIP, then their cell surface HLA-DR molecules will have bound CLIP. To assess this possibility, live MCF10/DR7/CD80/Ii cells were stained with the CerCLIP mAb which detects MHC II/CLIP complexes (Fig. 3a) . MCF10/DR7/CD80/Ii cells express approximately the same amount of HLA-DR/ CLIP complexes at the cell surface as the B cell lymphoma Sweig, which constitutively expresses HLA-DR, Ii, and DM. As expected, MCF10/DR7/CD80 cells do not express HLA-DR/CLIP complexes at the cell surface since they do not contain Ii. Therefore, MCF10/DR7/CD80/Ii cells do not express signiWcantly higher levels of CLIP than Sweig cells, making it unlikely that their reduced antigen presentation activity is due to excessive levels of CLIP interfering with MHC II-restricted peptide presentation.
Because professional APC such as DC express DM, we have prepared MHC II vaccines using the MHC class II transactivator (CIITA), which coordinately up-regulates MHC II, Ii, and DM [15] , and an siRNA to down-regulate Ii (MCF10/CIITA/CD80/Ii siRNA cells) [47] . As measured by Xow cytometry, these vaccine cells express high levels of HLA-DR, very low levels of HLA-DR/CLIP complexes at the cell surface (Fig. 3a) , and levels of HLA-DM similar to Sweig cells (Fig. 3b) . Since PBMC that are syngeneic to the MCF10 vaccines are not available, and CIITA up-regulates all HLA-DR, -DP, and DQ alleles, the CIITA transductants cannot be used as priming agents because they will induce MHC II allogeneic responses. However, allogeneic T cell activation should not occur during the short duration of the boosting response, so the CIITA transductants can be used as boosting agents. from DR7 + healthy human donors were primed and boosted with Ii ¡ (MCF10/DR7/CD80) or Ii + (MCF10/DR7/CD80/ Ii) cells, and the non-adherent cells were harvested and triple-stained for CD4 and 24 diVerent TcR V s. The CD4 + T cells were gated (Fig. 5a ) and analyzed for V expression. Figure 5b shows the TCR V family usage by CD4 + T cells from healthy donors 123104 and 100704 before and after activation with either the Ii ¡ or Ii + cells. Table 1 [7] . These Wndings are also corroborated by biochemical studies in which mass spectroscopy analysis of MHC II-bound peptides demonstrated that Ii ¡ APC display peptides that are not presented by Ii + APC [28] . The presentation of diVerent and/or more immunogenic epitopes by Ii ¡ MHC II vaccines may also be due to the presentation of "cryptic" peptides, a term coined by investigators studying autoimmunity. Cryptic peptides are peptides that are not presented in the thymus during central tolerance induction, but are present in the periphery and which bind with high aYnity to MHC molecules. Such peptides have been identiWed and shown to induce T cell responses to self antigens [4, 17, 24, 39] . If the absence of Ii in MHC II vaccine cells results in altered antigen processing and presentation, as we have hypothesized, then the vaccine cells may present cryptic tumor peptides which potentially induce a more robust CD4 + T cell response. The MCF10/DR7/CD80 and MCF10/CIITA/CD80/ siRNA vaccines both activate tumor-reactive CD4 + T cells in the absence of Ii and have the potential to be clinically useful. We have proposed using the vaccines in non-autologous patients who are HLA-DR-matched to the vaccine cells, to avoid customized vaccine preparation for individual patients [8] . high [11] . Since the failure to remove CLIP from MHC II molecules reduces endogenous antigen presentation [25] , this observation is consistent with the concept that HLA-DR expression in the absence of Ii favors the activation of tumor-reactive CD4 + T cells. Similarly, the co-expression of Ii by HLA-DR + hepatocellular carcinoma cells is associated with a very poor prognosis [46] . Likewise, tumor cell expression of an isoform of Ii that blocks endogenous antigen presentation is associated with poor prognosis in chronic lymphocytic leukemia patients [48] . If the vaccine cells are the actual APC in vivo, then they may be particularly useful for treating cancer patients whose DC are dysfunctional due to tumor burden [26, 27] . If the vaccine cells are not the relevant APC in vivo, and CD4 + T cells are activated via cross-dressing [14] or by conventional antigen presentation via DC, then the vaccines are useful reagents for producing novel peptide-MHC complexes. Regardless of the precise mechanism by which the MHC II vaccines activate tumor-reactive CD4 + T cells, they eYciently prime and boost CD4 + T cells, and the absence of Ii is critical for their activity.
